Bristol-Myers Squibb Co. (BMY) Raises Project Pipeline Revenue Guidance at Analyst Day - Morgan Stanley

November 17, 2021 6:22 AM EST Send to a Friend
Morgan Stanley analyst Matthew Harrison reiterated an Equalweight rating and $66.00 price target on Bristol-Myers Squibb Co. (NYSE: BMY) after ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login